Versartis Культура компании

Mr. Jay P. Shepard has been the President and Chief Executive Officer at Versartis, Inc. since May 6, 2015. Mr. Shepard has been Principal Financial Officer of Versartis, Inc. since December 1, 2017. He served as an Executive Partner of Sofinnova Ventures, Inc. He served as the Chairman and Chief Executive Officer of NextWave Pharmaceuticals, Inc. from January 1, 2010 to November 2012 and its President until November 2012. He was employed at InterMune Inc. He originally joined Sofinnova in 2008 as an Executive in Residence and was its Venture Partner. Mr. Shepard served as an Executive in Residence at Sofinnova Ventures, Inc. since 2008 and also served as its Venture Partner. He served as the Chief Executive Officer and President of Relypsa, Inc., where he also worked as Interim President. He served as the Chief Executive Officer and Co-President of Ilypsa, Inc., and joined in December 2005. He served as Vice President of Commercial Operations of Telik Inc., since August 2002. Prior to joining Telik Inc., from 1994 to 2002, he held positions of increasing responsibility with Alza Pharmaceuticals, Inc. He served as Vice President of Oncology Business Unit at ALZA Pharmaceuticals Oncology Business Unit, having held leadership positions in its specialty pharmaceutical sales and marketing group. He was responsible for a product line that included Doxil???. Prior to 1994, he held product and sales management positions with Syntex Laboratories and Ortho Pharmaceutical Corporation. He served as an Executive Chairman of Versartis, Inc. since December 2013 until May 6, 2015 and has been its Director since December 2013. He has been an Independent Director of Sorbent Therapeutics, Inc. since June 18, 2014. He served as an Independent Director of Marinus Pharmaceuticals, Inc. since November 2013 until May 11, 2017. He served as a Director of DURECT Corporation from September 26, 2013 to August 16, 2016. He served as a Director at Bullet Biotechnology, Inc. He served as a Director of Relypsa, Inc. until September 2010. He served as an Executive Director of NextWave Pharmaceuticals, Inc. and Ilypsa, Inc. He has more than 33 years experience in the pharmaceutical, biotechnology and drug delivery arenas. Mr. Shepard holds a Bachelor of Science Degree in Business Administration from the University of Arizona, Tucson.

Dr. Joshua Silverman, also known as Josh, Ph.D is the Co-Founder of Calysta, Inc. an serves as its Chief Product & Innovation Officer. Dr. Silverman serves as an Advisor for a number of biotechnology companies. He served as Chief Scientific Officer of Calysta, Inc. He served as Vice President of Drug Development at Amunix, Inc. (AKA Amunix Operating Inc.). He is an experienced biotechnology entrepreneur with a history of successful development of novel technology platforms. He served positions at two public biotechnology companies, Maxygen, Inc. and Amgen, Inc. He co-founded Versartis, Inc. in 2008. He involved in the founding and financing of five startup biotechnology companies (Avidia, Diartis, Siluria and Calysta). He is generally interested in tools and applications of biological engineering as a robust and predictable engineering discipline. He is a frequent speaker at scientific meetings. He is an author on more than 10 scientific publications as well as over 30 patents and pending patent applications. He has B.Sc. in Molecular Biology from UC San Diego and Ph.D. in Biochemistry from Stanford University.

Dr. Jeffrey L. Cleland, also known as Jeff, Ph.D., is the president of Ashvattha Therapeutics, LLC. Dr. Cleland serves as Chief Executive Officer, President and Director of Graybug Vision, Inc. He served as Interim Chief Executive Officer of GrayBug, Inc since May 2015. Dr. Cleland Co-Founded Versartis, Inc. in 2008 and has been Senior Scientific Advisor to the Chief Executive Officer since May 6, 2015. Dr. Cleland served as Chief Executive Officer and President of Versartis, Inc. from May 2009 to May 6, 2015. Dr. Cleland founded Diartis Pharmaceuticals, Inc. in 2010 and serves as its Chief Executive Officer. He serves as a Director of Targesome Inc. Dr. Cleland serves as Vice President of Therapeutic Development of ProFoldRx, Inc. Previously, Dr. Cleland served as Vice President of Research & Development for Targesome Inc. He served as Vice President of Therapeutic Development of BaroFold Inc. He served as Vice President of Technical Operations at Novacea Inc. Dr. Cleland led the development of Nutropin Depot from concept to approval and co-led the manufacturing subteam for Herceptin through approval in both the U.S. and Europe. He has over 20 years of industry experience, includes more than a decade at Genentech, Inc., in drug development, manufacturing, delivery and formulation. He held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. His experience in startups includes major roles in obtaining more than $350 M in capital at stages from Series A through D and exit via IPO including over $250 M in capital raised as Chief Executive Officer. While at Genentech, he served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin??? and Nutropin Depot???, as well as in early work on Lucentis???, Avastin???, and Omnitarg???. Prior to Novacea, Dr. Cleland founded Pharmaceutical Development, Manufacturing & Delivery Consultants (PDMDC) and then served as its President. He served in product development and manufacturing roles at Genentech, including served as its Senior Scientist and Group Leader for pharmaceutical research and development. He serves as Director of GrayBug, LLC. Dr. Cleland served as a Director of Versartis, Inc. since May 2009. He serves as a Director of Diartis Pharmaceuticals, Inc. He is an author on over 90 manuscripts and serves on the editorial board of 5 journals in the field of pharmaceutical sciences. His contributions to pharmaceutical sciences have been internationally recognized by his election as a Fellow of the American Association of Pharmaceutical Sciences and the International Controlled Release Society Young Investigator Award for Excellence in Research. Dr. Cleland is an Adjunct Assistant Professor at University of the Pacific, University of Kansas and University of Colorado. He has authored more than 100 articles and 4 books, and holds several issued patents. He holds a BS in Chemical Engineering from the University of California, Davis and a Ph.D in Chemical Engineering from the Massachusetts Institute of Technology.

R Greer serves as the Director of Versartis, Inc.. R started at Versartis, Inc. in December of 2014. R currently resides in Phoenix, Arizona Area.

Paul Westberg serves as the Chief Business Officer of Versartis, Inc.. Paul started at Versartis, Inc. in March of 2010. Paul currently resides in San Francisco Bay Area.

Tracy Woody serves as the Chief Commercial Officer of Versartis, Inc.. Tracy started at Versartis, Inc. in March of 2017. Tracy currently resides in San Francisco Bay Area.

Will Charlton serves as the Senior Medical DIrector and Head of Pharmacovigilance at Versartis of Versartis, Inc.. Will currently resides in the San Francisco Bay Area.

Kevin Haas serves as the VP Finance Principal Accounting Officer of Versartis, Inc.. Kevin currently resides in the San Francisco Bay Area.

Greg Yedinak serves as the VP,Device and Pharmaceutical Development of Versartis, Inc.. Greg currently resides in the San Francisco Bay Area.